Kca3.1 channel modulators as potential therapeutic compounds for glioblastoma

Brandon M. Brown, Brandon Pressley, Heike Wulff

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 is widely expressed in cells of the immune system such as T-and B-lymphocytes, mast cells, macrophages and microglia, but also found in dedifferentiated vascular smooth muscle cells, fibroblasts and many cancer cells including pancreatic, prostate, leukemia and glioblastoma. In all these cell types KCa3.1 plays an important role in cellular activation, migration and proliferation by regulating membrane potential and Ca2+ signaling. Methods and Results: KCa3.1 therefore constitutes an attractive therapeutic target for diseases involving excessive proliferation or activation of one more of these cell types and researchers both in academia and in the pharmaceutical industry have developed several potent and selective small molecule inhibitors of KCa3.1. This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer’s disease. Conclusion: Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials.

Original languageEnglish (US)
Pages (from-to)618-626
Number of pages9
JournalCurrent Neuropharmacology
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Glioblastoma
Microglia
Calcium-Activated Potassium Channels
Phase III Clinical Trials
Drug Industry
Therapeutics
Vascular Smooth Muscle
Mast Cells
Brain Neoplasms
Membrane Potentials
Smooth Muscle Myocytes
Prostate
Immune System
Alzheimer Disease
Leukemia
B-Lymphocytes
Animal Models
Fibroblasts
Stroke
Macrophages

Keywords

  • Glioblastoma
  • K3.1
  • Neuroinflammation
  • NS6180
  • Repurposing
  • Senicapoc
  • TRAM-34

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kca3.1 channel modulators as potential therapeutic compounds for glioblastoma. / Brown, Brandon M.; Pressley, Brandon; Wulff, Heike.

In: Current Neuropharmacology, Vol. 16, No. 5, 01.01.2018, p. 618-626.

Research output: Contribution to journalReview article

Brown, Brandon M. ; Pressley, Brandon ; Wulff, Heike. / Kca3.1 channel modulators as potential therapeutic compounds for glioblastoma. In: Current Neuropharmacology. 2018 ; Vol. 16, No. 5. pp. 618-626.
@article{efc61ce8070741ed9868d366fce51515,
title = "Kca3.1 channel modulators as potential therapeutic compounds for glioblastoma",
abstract = "Background: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 is widely expressed in cells of the immune system such as T-and B-lymphocytes, mast cells, macrophages and microglia, but also found in dedifferentiated vascular smooth muscle cells, fibroblasts and many cancer cells including pancreatic, prostate, leukemia and glioblastoma. In all these cell types KCa3.1 plays an important role in cellular activation, migration and proliferation by regulating membrane potential and Ca2+ signaling. Methods and Results: KCa3.1 therefore constitutes an attractive therapeutic target for diseases involving excessive proliferation or activation of one more of these cell types and researchers both in academia and in the pharmaceutical industry have developed several potent and selective small molecule inhibitors of KCa3.1. This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer’s disease. Conclusion: Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials.",
keywords = "Glioblastoma, K3.1, Neuroinflammation, NS6180, Repurposing, Senicapoc, TRAM-34",
author = "Brown, {Brandon M.} and Brandon Pressley and Heike Wulff",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570159X15666170630164226",
language = "English (US)",
volume = "16",
pages = "618--626",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Kca3.1 channel modulators as potential therapeutic compounds for glioblastoma

AU - Brown, Brandon M.

AU - Pressley, Brandon

AU - Wulff, Heike

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 is widely expressed in cells of the immune system such as T-and B-lymphocytes, mast cells, macrophages and microglia, but also found in dedifferentiated vascular smooth muscle cells, fibroblasts and many cancer cells including pancreatic, prostate, leukemia and glioblastoma. In all these cell types KCa3.1 plays an important role in cellular activation, migration and proliferation by regulating membrane potential and Ca2+ signaling. Methods and Results: KCa3.1 therefore constitutes an attractive therapeutic target for diseases involving excessive proliferation or activation of one more of these cell types and researchers both in academia and in the pharmaceutical industry have developed several potent and selective small molecule inhibitors of KCa3.1. This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer’s disease. Conclusion: Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials.

AB - Background: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 is widely expressed in cells of the immune system such as T-and B-lymphocytes, mast cells, macrophages and microglia, but also found in dedifferentiated vascular smooth muscle cells, fibroblasts and many cancer cells including pancreatic, prostate, leukemia and glioblastoma. In all these cell types KCa3.1 plays an important role in cellular activation, migration and proliferation by regulating membrane potential and Ca2+ signaling. Methods and Results: KCa3.1 therefore constitutes an attractive therapeutic target for diseases involving excessive proliferation or activation of one more of these cell types and researchers both in academia and in the pharmaceutical industry have developed several potent and selective small molecule inhibitors of KCa3.1. This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer’s disease. Conclusion: Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials.

KW - Glioblastoma

KW - K3.1

KW - Neuroinflammation

KW - NS6180

KW - Repurposing

KW - Senicapoc

KW - TRAM-34

UR - http://www.scopus.com/inward/record.url?scp=85039964451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039964451&partnerID=8YFLogxK

U2 - 10.2174/1570159X15666170630164226

DO - 10.2174/1570159X15666170630164226

M3 - Review article

VL - 16

SP - 618

EP - 626

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 5

ER -